ArticleAmerican journal of physiology. Renal physiology2011
Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.
Article in American journal of physiology. Renal physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- MMPs at Work: Deciphering Their Role in the Cellular Mechanisms of Orthodontic Tooth Movement.International journal of molecular sciences · 2026Review
- Kidney-specific delivery of a matrix metalloproteinase-2 inhibitory peptide fused to elastin-like polypeptide reduces proteinuria and renal fibrosis in a model of salt-sensitive hypertension.The Journal of pharmacology and experimental therapeutics · 2025Article
- Gelatin Zymography to Quantify Levels of MMP-2 and MMP-9 in Complex Biological Samples.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Matrix metalloproteinases in kidney homeostasis and diseases: an update.American journal of physiology. Renal physiology · 2024Review
- Matrix metalloproteinase-9 regulates afferent arteriolar remodeling and function in hypertension-induced kidney disease.Kidney international · 2023Article
- Snakebite drug discovery: high-throughput screening to identify novel snake venom metalloproteinase toxin inhibitors.Frontiers in pharmacology · 2023Article
- Key metalloproteinase-mediated pathways in the kidney.Nature reviews. Nephrology · 2021Review
- Knockout ofThe Journal of pharmacology and experimental therapeutics · 2021Article
- MicroRNA and mRNA analysis of angiotensin II-induced renal artery endothelial cell dysfunction.Experimental and therapeutic medicine · 2020Article
- Matrix Metalloproteinases in Diabetic Kidney Disease.Journal of clinical medicine · 2020Review
- Progression of diabetic kidney disease in T2DN rats.American journal of physiology. Renal physiology · 2019Article
- Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.Pharmacology & therapeutics · 2019Review
- Article
- Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?American journal of physiology. Renal physiology · 2016Review
- Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE.Clinical immunology (Orlando, Fla.) · 2016Article
- Matrix Metalloproteinases in Non-Neoplastic Disorders.International journal of molecular sciences · 2016Review
- Fluorescence dilution technique for measurement of albumin reflection coefficient in isolated glomeruli.American journal of physiology. Renal physiology · 2015Article
- Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor.Cardiovascular research · 2015Article
- Present and future in the treatment of diabetic kidney disease.Journal of diabetes research · 2015Review
- To cleave or not to cleave: role of ADAM17 in cell proliferation in PKD.American journal of physiology. Renal physiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
This study examined the effects of two new selective metalloprotease (MMP) inhibitors, XL081 and XL784, on the development of renal injury in rat models of hypertension, Dahl salt-sensitive (Dahl S) and type 2 diabetic nephropathy (T2DN). Protein excretion rose from 20 to 120 mg/day in Dahl S rats fed a high-salt diet (8.0% NaCl) for 4 wk to induce hypertension. Chronic treatment with XL081 markedly reduced proteinuria and glomerulosclerosis, but it also attenuated the development of hypertension. To determine whether an MMP inhibitor could oppose the progression of renal damage in the absence of changes in blood pressure, Dahl S rats were fed a high-salt diet (4.0% NaCl) for 5 wks to induce renal injury and then were treated with the more potent and bioavailable MMP inhibitor XL784 either given alone or in combination with lisinopril and losartan. Treatment with XL784 or the ANG II blockers reduced proteinuria and glomerulosclerosis by ~30% and had no effect on blood pressure. Proteinuria fell from 150 to 30 mg/day in the rats receiving both XL784 and the ANG II blockers, and the degree of renal injury fell to levels seen in normotensive Dahl S rats maintained from birth on a low-salt diet. In other studies, albumin excretion rose from 125 to >200 mg/day over a 4-mo period in 12-mo-old uninephrectomized T2DN rats. In contrast, albumin excretion fell by >50% in T2DN rats treated with XL784, lisinopril, or combined therapy. XL784 reduced the degree of glomerulosclerosis in the T2DN rats to a greater extent than lisinopril, and combined therapy was more effective than either drug alone. These results indicate that chronic administration of a selective MMP inhibitor delays the progression, and may even reverse hypertension and diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.